DGAP-News: Biotest AG / Key word(s): Takeover
31.01.2018 / 18:00
The issuer is solely responsible for the content of this announcement.
Creat takeover of Biotest closed
– Transfer of tendered shares completed
– Majority shareholding (approx. 90% of Biotest AG’s ordinary shares and voting share capital) of Creat in Biotest
Dreieich, 31 January 2018. On 19 January 2018 Biotest AG disclosed that the last remaining condition has been met for the takeover offer by Tiancheng (Germany) Pharmaceutical Holdings AG, the acquisition company of the Creat Group Corporation. Thus the unsolicited takeover offer announced on 18 May 2017 for the shares of Biotest AG became effective and could be settled.
The offer by Tiancheng (Germany) Pharmaceutical Holdings AG and payment of the purchase price to the custodial bank of the accepting Biotest shareholders was settled promptly and, as described in section 13.5 of the offer document.
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
31.01.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||0 61 03 – 8 01-0|
|Fax:||0 61 03 – 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|End of News||DGAP News Service|